Modality
ERT
MOA
PI3Ki
Target
VEGF
Pathway
Complement
PBCMGLN
Development Pipeline
Preclinical
~Apr 2022
→ ~Jul 2023
Phase 1
~Oct 2023
→ ~Jan 2025
Phase 2
Apr 2025
→ Jan 2026
Phase 2Current
NCT05379095
796 pts·PBC
2025-04→2026-01·Not yet recruiting
796 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-01-232mo agoPh3 Readout· PBC
Trial Timeline
Q2Q3Q42026
P2/3
Not yet…
Catalysts
Ph3 Readout
2026-01-23 · 2mo ago
PBC
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05379095 | Phase 2/3 | PBC | Not yet recr... | 796 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| Bemazumab | Regeneron | Phase 1 | VEGF |